STOCK TITAN

BeOne Medicines (ONC) Form 144: 5,000 ADS Sale Planned; 7,675 ADS Sold Recently

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

BeOne Medicines Ltd. (ONC) Form 144 notice: The filer notified a proposed sale of 5,000 ADS through Morgan Stanley Smith Barney at an aggregate market value of $1,732,250.00, with an approximate sale date of 09/09/2025 on NASDAQ. The securities were acquired on 05/17/2022 by previously exercised stock options and paid in cash. The filing also discloses recent sales by the related parties: 7,675 ADS were sold during the past three months in multiple transactions generating gross proceeds of $2,210,354.28. The filer affirms no undisclosed material adverse information and, where applicable, reliance on a trading plan or instructions is noted in the form.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Insider-related sales disclosed: planned 5,000 ADS sale and 7,675 ADS sold recently, totaling over $2.2M proceeds.

The filing clearly lists a proposed sale of 5,000 ADS (aggregate market value $1.73M) to be executed via Morgan Stanley Smith Barney on 09/09/2025 and documents acquisition by exercised options paid in cash on 05/17/2022. Recent dispositions by related parties and the named individual (Lai Wang and Wang Holdings LLC) total 7,675 ADS with gross proceeds of $2,210,354.28. For investors, these are transparent disclosures of insider liquidity events; the filing does not provide reasons for selling or any forward-looking plans beyond the stated dates.

TL;DR: Governance disclosure is routine and complete for a Form 144; signatures and representations are included.

The form includes the required representation that the seller is unaware of undisclosed material adverse information and references potential reliance on Rule 10b5-1 plans. Acquisition details (date and nature) and payment form are provided, meeting the form's disclosure standards. The record of multiple recent sales by related parties should be evaluated in the context of corporate governance and insider trading policies, but the filing itself contains the necessary factual information without commentary.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for ONC disclose about the proposed sale?

The notice reports a proposed sale of 5,000 ADS through Morgan Stanley Smith Barney with an aggregate market value of $1,732,250.00 and an approximate sale date of 09/09/2025.

How and when were the ADS being sold acquired according to the filing?

The 5,000 ADS were acquired on 05/17/2022 through previously exercised stock options and payment was made in cash.

What insider or related-party sales occurred in the last three months per the filing?

The filing shows five transactions totaling 7,675 ADS sold by Wang Holdings LLC and Lai Wang on dates between 06/16/2025 and 07/29/2025, with combined gross proceeds of $2,210,354.28.

Does the filer state they have undisclosed material information?

By signing the form, the person represents they do not know of any material adverse information

Is there an indication the sales are part of a Rule 10b5-1 plan?

The filing references Rule 10b5-1 sales and includes a field for the date of plan adoption or instruction; specific plan adoption dates are included where applicable in the form.

Which exchange is listed for the proposed sale of ADS?

The proposed sale lists NASDAQ as the securities exchange for the transaction.
BeOne Medicines Ltd.

NASDAQ:ONC

ONC Rankings

ONC Latest News

ONC Latest SEC Filings

ONC Stock Data

34.50B
90.70M
17.24%
32.38%
1.35%
Biotechnology
Pharmaceutical Preparations
Link
Switzerland
BASEL